Tango Therapeutics, Inc.
TNGXNASDAQHealthcareBiotechnology
Regular session
$24.1255
+$0.2455 · +1.03%
TNGX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
57
Fair Value
Momentum
71
Gaining
Sentiment
70
Bullish
Risk resilience
56
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteTango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Malte Peters
- Listed since
- Sep 3, 2020
- Employees
- 137
Market position
Day range
Current $24.1255
52-week range
Current $24.1255
- Open
- $23.60
- Previous close
- $23.88
- Volume
- 726.28K
- 0.2× average
- Average volume
- 3.59M
- Average daily volume
- Market cap
- 3.93B USD
- Beta
- 1.15
- Market reference 1
- 50-day average
- $28.415
- -15.10% below average
- 200-day average
- $18.8131
- +28.24% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -28.38×
- P/B (TTM)
- 3.53×
- P/S (TTM)
- 73×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 98.25%
- Operating margin
- -253.38%
- Net margin
- -229.92%
Financial health
- Debt / equity
- 0.03×
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
13 ratingsTNGX peers
Continue in GoAI
Research TNGXresearch.disclaimer